morgans

Sirtex is still trading 33% below its level prior to last week’s trading update. Issues such as competition, reimbursement, complex work-up, short sales cycle, and the first admission that SIRFLOX survival data is needed to drive front-line use were cited as causes for the weakness. While these issues are nothing... Show More

Chris Titley

I recently sat down with the inspirational Maxine Horne from Vita Group . A fabolous success story, we talk about the history of the business and how it's grown, work/life balance as a mother , her involvement in philanthropy , gender diversity and some words of advice for entrepreneurs. Show More

The market is currently pricing in a 74% chance of the first official interest rate increase in the US when the FOMC meets on the 15-16 December. We advise against complacency ahead of this, as volatility can very quickly erode confidence. We suggest investors stick to stocks with higher levels... Show More

Markets have arrested their recent falls, not because fundamentals are improving, but because central bank actions have effectively prolonged the era of easy monetary policy. Fickle market activity may be prolonged until there is a clearer picture on the eventual normalisation of monetary policy. Nonetheless, select companies can still thrive... Show More

Belinda Moore, Senior Analyst at Morgans, provides a short presentation on Vitaco Holdings (ASX:VIT). Vitaco is a recent listing on the ASX and Morgans have initiated coverage on the stock with a 'Buy' rating and a price target of $3.25. Watch the full presentation by clicking on the image below.... Show More